Table 3.
Cost-effectiveness results among patients with ≥ 1 rCDI
| Outcomes | FMBL | SOC |
|---|---|---|
| Cost (2022 USD) | ||
| Total costs | $79,236 | $73,900 |
| Drug acquisition and administration costs | $24,245 | $16,876 |
| Medical costs | $54,991 | $57,024 |
| Effectiveness | ||
| Total QALYs | 10.346 | 10.061 |
| Total LYs | 12.504 | 12.240 |
| Incremental outcome of FMBL vs. SOC | ||
| Incremental costs | $5336 | |
| Incremental QALYs | 0.285 | |
| Incremental LYs | 0.264 | |
| ICER of FMBL vs. SOC (2022 USD) | ||
| Incremental cost per QALY gained | $18,727 | |
| Incremental cost per LY gained | $20,186 | |
ICER results are subject to rounding errors. Precise values of costs and effectiveness with more decimals were used in the model calculation
FMBL fecal microbiota, live-jslm, ICER incremental cost-effectiveness ratio, LY life year, QALY quality-adjusted life year, SOC standard of care, USD United States dollar